Effect of Xuezhikang Combined with Aliciumab on the LDL-C Attainment Rate and Other Blood Lipid Indicators of Statin-Intolerant Patients with ASCVD
Objective To investigate the value of Xuezhikang combined with Aliciumab in statin-intolerant patients with atherosclerotic cardiovascular disease(ASCVD).Methods From June 2022 to September 2023,80 patients with ASCVD who were intolerant to statins were selected and divided into the research group(n =40)and the control group(n = 40)according to different treatment methods.The research group was treated with Xuezhikang combined with Aliciumab,while the control group was treated with Aliciumab.Low-density lipoprotein cholesterol(LDL-C)and other blood lipid indica-tors[total cholesterol(TC),high-density lipoprotein cholesterol(HDL-C),and triglycerides]before treatment and at 4,8,and 12 weeks after treatment,as well as the LDL-C attainment rate and a reduction of>50%attainment rate at 4 weeks after treatment and the occurrence of adverse reactions during treatment were compared between the two groups.Results Com-pared with that before treatment,the LDL-C level at 4,8 and 12 weeks after treatment decreased in both groups,which was lower in the research group than in the control group(P<0.05).Compared with those before treatment,at 4,8,and 12 weeks after treatment,TC and triglyceride in both groups decreased,HDL-C in both groups increased(P<0.05).At 4,8,and 12 weeks after treatment,TC of the research group was lower than that of the control group(P<0.05).At 4 weeks after treatment,the LDL-C attainment rate and a reduction of>50%attainment rate in the research group were higher than those in the control group(P<0.05).During the treatment period,there was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion In patients with ASCVD who are intolerant to statins,the combi-nation of Xuezhikang and Aliciumab can improve the level of blood lipids and increase LDL-C attainment rate,with high safety and favorable prognosis.
万方数据
维普
